8-K

================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


                       DATE OF REPORT - December 11, 2001
                        (Date of Earliest Event Reported)


                           COLUMBIA LABORATORIES, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                           Commission File No. 1-10352


        Delaware                                                59-2758596
- ------------------------                                     ----------------
(State of Incorporation)                                     (I.R.S. Employer
                                                            Identification No.)

  220 South Orange Avenue, 2nd Floor
- -----------------------------------------
       Livingston, New Jersey                                   07039
       (Address of principal                                  ----------
         executive offices)                                    Zip Code


       Registrant's telephone number, including area code: (516) 766-2847

================================================================================





ITEM 5.    OTHER EVENTS.

                During the period December 4, 2001 through December 11, 2001,
Columbia Laboratories, Inc. (the "Company") sold an aggregate of 1,118,866
shares of its common stock to various investors at a purchase price of $2.65 per
share (representing a negotiated discount to the market price), for aggregate
gross proceeds to the Company of $2,965,000.

                On December 12, 2001, the Company issued the press release
attached hereto as Exhibit 99.1.


ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

                (c) Exhibits.

                      99.1         Press Release dated December 12, 2001.








                                       2

                                    SIGNATURE

                Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.


Date:  December 12, 2001

                                      COLUMBIA LABORATORIES, INC.

                                      By: /s/ David L. Weinberg
                                          -----------------------------------
                                          Name: David L. Weinberg
                                          Title: Chief Financial Officer



















                                       3

                                 EXHIBIT INDEX



             99.1         Press Release dated December 12, 2001.

EX-99

                                                                  Exhibit 99.1

PRESS RELEASE

COLUMBIA LABORATORIES SECURES APPROXIMATELY $3 MILLION IN EQUITY FINANCING
PARTICIPANTS INCLUDE SIX INSTITUTIONAL INVESTORS


LIVINGSTON, N.J.--(BUSINESS WIRE)--Dec. 12, 2001--Columbia Laboratories
(AMEX:COB) announced today that it has raised $2,965,000 in proceeds through a
private sale of 1,118,866 shelf-registered shares of common stock. Aqua
Wellington, Curran Partners and John Curran Affiliates, EGS Partners, Hillhouse
Capital, Irvine Capital and Knott Partners participated in the financing.

Fred Wilkinson, Columbia's president and chief executive officer said: "This
equity financing provides further financial support to accelerate our multiple
development programs, including the submission of worldwide registration
documents for our Testosterone Buccal Tablet for men, estimated to be filed in
the first quarter of 2002. In addition, this funding will provide the necessary
resources to cover corporate overhead for the next 12 months, and projected
legal expenses resulting from the Serono litigation. We feel that completing
this transaction is a safe and prudent strategy in protecting the assets and
interests of our shareholders."

Wilkinson added, "We are pleased by the level of support expressed by these
recognized institutional investors, and believe that the company will broaden
its investment appeal, in the near future, with the re-launch of Crinone, the
filing of Testosterone Buccal Tablet, the successful progression of additional
R & D projects and the introduction of additional products."

Funding for additional research and development expenses in 2002, to support the
clinical programs for Columbia's pipeline products including Lidocaine Vaginal
Gel, will be generated from projected increased revenues from additional
licensing agreements for Replens, Miphil and Advantage-S in Europe. The company
plans to introduce Miphil and Advantage-S under new trade names and marketing
strategies in early 2002. Columbia also expects to receive funds related to
establishing a marketing partner for Testosterone Buccal Tablet in non-U.S.
markets in early 2002.

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company
dedicated to research and development of women's health care and endocrinology
products, including those intended to treat infertility, dysmenorrhea,
endometriosis and hormonal deficiencies. Columbia is also developing hormonal
products for men and a buccal delivery system for peptides. Columbia's products
primarily utilize the company's patented bioadhesive delivery technology.

This press release contains statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Those statements include statements regarding the intent, belief or current


expectations of the company and its management team. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those projected in the forward-looking statements. Such
risks and uncertainties include, among other things, the successful revalidation
of the Crinone manufacturing process, timely and successful completion of
clinical studies, competitive economic and regulatory factors in the
pharmaceutical and health care industry, the outcome of the Serono litigation,
general economic conditions and other risks and uncertainties that may be
detailed, from time-to-time, in Columbia's reports filed with the Securities and
Exchange Commission.


- -----------------------------

Contact:
     Columbia Laboratories, Inc., Livingston
     James Apostolakis, 212/588-1900
     or
     David Weinberg, 973/994-3999
     or
     In-Site Communications, Inc.
     Lisa Carlton-Wilson, 212/759-3929













                                       2